A 31-trial meta-analysis and a sleep-deprivation EEG study offer the clearest evidence yet on the caffeine and L-theanine combo — a robust attention boost in healthy adults, with caveats on stress and mood claims.

Two studies published within months of each other have sharpened the picture of what the popular caffeine and L-theanine combination does — and does not do — for the human brain. One is the largest pooled analysis of L-theanine to date. The other tests the combination at high doses in people who have not slept.

Together they point to a consistent, if narrow, conclusion: the pairing reliably improves attention and reaction time in healthy adults, particularly when fatigue is a factor. The broader claims often attached to L-theanine — lasting stress relief, mood elevation, protection against burnout — remain far less certain.

A robust short-term effect on attention

Published in Molecular Psychiatry, a Nature journal, in July 2026, the systematic review and meta-analysis pooled 31 randomised controlled trials covering 1,168 participants. It compared oral L-theanine with placebo in both healthy and clinical populations.

The headline finding concerns a single dose. Taking 200 mg of L-theanine 30 to 60 minutes before cognitive testing significantly improved choice reaction time, with a standardised mean difference of 0.51 (95% confidence interval 0.25 to 0.77) — an effect size the authors describe as robust evidence of enhanced attention in healthy adults.

The news on stress was more modest. The reduction in acute stress after a single dose was small, with a standardised mean difference of 0.31, and the reviewers note it was largely driven by studies carrying a high risk of bias. No significant effect on fatigue emerged.

Anxiety results were inconsistent and generally non-significant, except in one study of psychotic anxiety that used 400 mg per day for eight weeks. On depressive symptoms, the picture is preliminary: after excluding a single outlier study, the analysis found a significant single-dose reduction in healthy individuals, but the authors are explicit that this needs confirmation in high-quality trials, especially in clinical groups.

On safety, the review found no serious adverse events and no meaningful difference in dropout rates between L-theanine and placebo.

Testing the combo under real-world fatigue

The second study, published in the British Journal of Nutrition and covered by PsyPost in October 2025, deliberately induced the condition in which people most often reach for these compounds.

Researchers led by Gayani Nawarathna at the University of Peradeniya ran a double-blind, placebo-controlled trial with 37 healthy adults aged 22 to 30. All were kept awake for 17 hours before testing. On separate days, each participant received either a capsule of 200 mg L-theanine plus 160 mg caffeine, or a placebo.

Participants completed a computerised traffic-safety task — pressing a button as fast as possible when an image signalled an imminent accident, while ignoring frequent images of safe driving. EEG recorded their brain activity throughout.

The combination improved both accuracy and reaction time. Participants identified imminent accidents more reliably and responded roughly 40 milliseconds faster on average than after the placebo. EEG data showed a stronger and faster P3b signal, a brainwave component linked to attention and decision-making.

Forty milliseconds is a small window in a laboratory task. The researchers' argument is that in driving, where the margin between noticing and not noticing can be the difference between a crash and near-miss, even a brief gain has practical weight. It is a reasonable framing, but it should be read as the rationale for a finding, not proof of a road-safety benefit.

Dosing, and where the evidence thins out

Both studies converge on higher doses than the early landmark research on this pairing. The foundational combination trial, Owen and colleagues in 2008, used only 50 mg caffeine with 100 mg L-theanine. The new work uses 200 mg L-theanine, paired with 160 mg caffeine in the sleep-deprivation study.

That matters for anyone reading supplement labels. Many commercial products use doses well below what the strongest recent evidence tests. It also means the results should not be generalised to every product marketed as a “calming focus” blend.

Several limits apply. The 37-participant trial is small and reports a single-session result in a young, healthy group; it is one data point, not a settled effect. The meta-analysis, while larger, is constrained by the underlying trials: heterogeneous designs, sometimes short follow-up, and the bias problems the authors themselves flag on the stress outcome. Effects seen right after a single dose do not tell us much about weeks or months of daily use.

Caffeine also carries real physiological effects — on heart rate, blood pressure, anxiety and sleep — and interacts with other stimulants and some medications. L-theanine is generally well-tolerated, but most trials study it alongside caffeine rather than in isolation.

What the evidence supports

For now, the defensible claim is narrow. In healthy adults, a single dose of around 200 mg of L-theanine improves attention and reaction time, and the combination with caffeine appears to help under acute sleep deprivation. The safety record is clean in the trials reviewed.

Claims about durable stress reduction, mood improvement or fatigue relief outrun the current data. The reviewers behind the largest analysis say as much themselves. On this subject, the gap between marketing and evidence is not closing quickly — but it is, at least, becoming easier to measure.